Prof. Glickman’s research delves into the hypothesis that the dysfunction of the ubiquitin system—a process responsible for clearing damaged proteins from cells—plays a key role in the development of Alzheimer's. The research team has created an experimental model that mimics the behavior of human nerve cells, providing a clearer view of how these protein clearance issues might contribute to neuron degeneration in the brain.

The ERC grant will support further exploration into identifying which components of the ubiquitin system are compromised in Alzheimer’s, aiming to uncover the mechanisms that trigger the disease at its onset. By targeting the root causes, the research could eventually pave the way for new treatments aimed at repairing brain damage in Alzheimer’s patients, offering hope for a condition that currently has no cure.
The ERC Advanced Grant is one of the highest accolades within Horizon Europe, designed to support pioneering research across a wide array of disciplines, including life sciences, physical sciences, and social sciences. This grant recognizes established researchers whose work promises groundbreaking discoveries, driving forward the frontiers of science and innovation.

Iliana Ivanova, Horizon Europe’s commissioner for Innovation, Research, Culture, Education, and Youth, highlighted the broader impact of these grants: “These grants will not only support leading researchers in pushing the boundaries of knowledge but will also create some 2,500 jobs for postdoctoral fellows, PhD students, and other research staff across Europe. This investment nurtures the next generation of brilliant minds.”

Prof. Glickman’s cutting-edge work exemplifies the kind of innovation that the ERC Advanced Grant aims to support, providing critical funding to unravel the complexities of neurodegenerative diseases like Alzheimer’s.